This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2002;287:1103.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved etanercept (Enbrel, Immunex Corp, Seattle, Wash), a dimeric fusion protein, for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis. The drug, an approved treatment for rheumatoid arthritis, can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

The new approval is based on the results of a study in 205 patients with active psoriatic arthritis (3 swollen joints and 3 tender joints) and plaque psoriasis with a target lesion of at least 2 cm in diameter. Patients could continue their regimen of up to 25 mg/wk of methotrexate. Doses of 25 mg of etanercept or placebo were administered subcutaneously twice a week for 6 months.

Compared with placebo, treatment with etanercept at 6 months resulted in significant (P<.001) improvements in measures of disease activity, whether or not patients were also taking methotrexate. . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diagnosis: Hereditary Type I Tyrosinema (hepatorenal tyrosinemia)
Rowe and Pohl
CLIN PEDIATR 2005;44:813-816.